Elevated Physiologic Tumor Pressure Promotes Proliferation and Chemosensitivity in Human Osteosarcoma

Purpose: This study investigates the effect of constitutively raised interstitial fluid pressure on osteosarcoma physiology and chemosensitivity. Experimental Design: We did pressure and blood flow assessments at the time of open biopsy in patients with the diagnosis of high-grade osteosarcoma and correlated this to survival and chemotherapy-associated tumor necrosis. Osteosarcoma cell lines were then evaluated for proliferative and therapeutic indices in a replicated high-pressure environment. Results: Sixteen osteosarcomas in vivo were assessed and exhibited elevated interstitial fluid pressures (mean 35.2 ± SD, 18.6 mmHg). This was not associated with significantly impeded blood flow as measured by a Doppler probe at a single site (P < 0.12). Nonetheless, greater chemotherapy-associated necrosis and associated longer survival were seen in tumors with higher interstitial fluid pressures (P < 0.05). In vitro, cells undergo significant physiologic changes under pressure. Osteosarcoma cell lines grown in a novel hydrostatically pressurized system had variable cell line–specific growth proportional to the level of pressure. They were more proliferative as indicated by cell cycle analysis with more cells in S phase after 48 hours of pressurization (P < 0.01). There was a significant elevation in the cell cycle–related transcription factors E2F-1 (P < 0.03) and E2F-4 (P < 0.002). These changes were associated with increased chemosensitivity. Cells tested under pressure showed an increased sensitivity to cisplatin (P < 0.00006) and doxorubicin (P < 0.03) reminiscent of the increased chemotherapy-associated necrosis seen in tumors with higher interstitial fluid pressure in the clinical study. Conclusions: The results of this study suggest that cells in the in vivo pressurized environment are at a higher state of regenerative activity than is demonstrable in conventional cell culture systems. Variations in tumor interstitial fluid pressure have the potential to alter chemotherapeutic effects.

[1]  Rakesh K. Jain,et al.  Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.

[2]  J H Goldie,et al.  Rationale for the use of alternating non-cross-resistant chemotherapy. , 1982, Cancer treatment reports.

[3]  S. Larson,et al.  Enhancing the Uptake of Chemotherapeutic Drugs into Tumors using an “Artificial Lymphatic System” , 2000, Annals of Biomedical Engineering.

[4]  R. Dedrick,et al.  Distribution of anticancer agents in spontaneous animal tumors. I. Regional blood flow and methotrexate distribution in canine lymphosarcoma. , 1974, Journal of the National Cancer Institute.

[5]  J. Healey,et al.  Interstitial Fluid Pressure and Blood Flow in Canine Osteosarcoma and Other Tumors , 2001, Clinical orthopaedics and related research.

[6]  E. Ercikan-Abali,et al.  Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. , 1996, Journal of the National Cancer Institute.

[7]  Dog Osteogenic Sarcoma Microvasculature Observed with a Spälteholz Technique , 2004, Clinical orthopaedics and related research.

[8]  R K Jain,et al.  Tumor angiogenesis and interstitial hypertension. , 1996, Cancer research.

[9]  R. Jain,et al.  Oncotic pressure in solid tumors is elevated. , 2000, Cancer research.

[10]  R K Jain,et al.  Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity. , 1996, Microvascular research.

[11]  R K Jain,et al.  Interstitial hypertension in superficial metastatic melanomas in humans. , 1991, Cancer research.

[12]  H. Cam,et al.  Emerging roles for E2F: beyond the G1/S transition and DNA replication. , 2003, Cancer cell.

[13]  G. Rosen,et al.  Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. , 1979, Cancer.

[14]  C. Cordon-Cardo,et al.  Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. , 2000, Cancer research.

[15]  R K Jain,et al.  Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. , 1990, Cancer research.

[16]  G. Rosen,et al.  Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. , 1977, Archives of pathology & laboratory medicine.

[17]  S. Larson,et al.  “Artificial Lymphatic System”: A New Approach to Reduce Interstitial Hypertension and Increase Blood Flow, pH and pO2 in Solid Tumors , 2000, Annals of Biomedical Engineering.

[18]  J. Gross,et al.  Hemodynamic characteristics in microcirculatory blood channels during early tumor growth. , 1979, Cancer research.

[19]  M. Fox,et al.  A model for the computer analysis of synchronous DNA distributions obtained by flow cytometry. , 1980, Cytometry.

[20]  R K Jain,et al.  Interstitial hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation response. , 1991, Cancer research.

[21]  Rakesh K. Jain,et al.  Pathology: Cancer cells compress intratumour vessels , 2004, Nature.

[22]  R K Jain,et al.  Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. , 1992, Cancer research.

[23]  Paolo A. Netti,et al.  Solid stress inhibits the growth of multicellular tumor spheroids , 1997, Nature Biotechnology.

[24]  K Messmer,et al.  Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. , 1992, Cancer research.

[25]  H. Abrams,et al.  Tumor perfusion in relation to the rapid growth phase and necrosis: studies on the Walker carcinoma in the rat testicle. , 1982, Microvascular research.

[26]  G Rosen,et al.  Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Rosen,et al.  Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy , 1982, Cancer.